Dacomitinib is an oral kinase inhibitor that can block the signaling pathway of tumor cells through its unique mechanism of action, inhibit tumor cell proliferation and growth, and achieve the effect of treating tumors.

1、 Drug name

1. Common name: Dacomitinib

2. Product Name: VIZIMPRO ®

2、 Indications

Used for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with confirmed EGFR exon 19 deletion or exon 21L858R substitution mutation through FDA approved testing.

3、 Specifications and characteristics

1. Specifications: 15mg, 45mg film coated tablets

2. Appearance: Tablets

4、 Main components

1. Active ingredient: Dakatinib

5、 Usage and dosage

1. Recommended dosage: 45mg orally once daily.

2. Medication time: taken at a fixed time every day, can be taken with food or on an empty stomach.

6、 Dose adjustment

1. Adverse reaction dose adjustment

Reduce the initial dose to 30mg once daily.

Reduce the second dose to 15mg once daily.

2. Specific Adverse Reaction Management

Interstitial lung disease (ILD): permanent discontinuation of medication after diagnosis.

Diarrhea: pause at level 2 until recovery to ≤ level 1 before continuing with the original dose; Relapsed grade 2 or 3-4, pause until recovery to ≤ grade 1, and then continue to reduce dosage.

Skin adverse reactions: persistent grade 2 pause until the original dose is resumed after recovery; Relapsed grade 2 or 3-4, pause until recovery and continue to reduce dosage.

7、 Medication precautions

1. Before and after meals: can be taken.

2. Omission treatment: Do not supplement the missed dose, continue with the next medication according to the original plan.

3. Vomiting treatment: No additional dosage will be taken, continue with the next planned medication.

8、 Medication for special populations

1. Pregnant women: May cause fetal damage, effective contraception is necessary during medication.

2. Breastfeeding period: It is not recommended to breastfeed during the treatment period and for at least 17 days after the last dose.

3. Elderly: Patients over 65 years old have a higher incidence of adverse reactions.

4. Liver and kidney dysfunction: No dose adjustment is needed for mild to moderate cases, and the dose for severe patients has not yet been determined.

9、 Adverse reactions

1. The most common adverse reactions (incidence>20%) are diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, weight loss, hair loss, cough, and itching.

2. Serious adverse reactions include interstitial lung disease, severe diarrhea, skin adverse reactions, etc.

10、 Contraindications

No clear contraindications

11、 Drug interactions

1. Proton pump inhibitors (PPIs): Avoid co administration.

2. H2 receptor antagonist: Use at least 6 hours before or 10 hours after taking VIZIMPRO.

3. CYP2D6 substrate: Avoid co use as it may increase toxicity risk.

12、 Storage method

Store at 20 ° C to 25 ° C, allowing fluctuations between 15 ° C and 30 ° C.

13、 Important Warning

1. Monitor lung symptoms and be alert to interstitial lung disease.

2. Timely treatment of diarrhea and prevention of dehydration.

3. Pay attention to sun protection and use moisturizers to prevent skin reactions.

4. Effective contraceptive measures should be taken during the medication period for women of childbearing age.

Dacomitinibinformation